Postdoctoral Career Development Fellow
As part of the Oxford Parkinson’s disease centre my research is based around characterising the earliest pathogenic changes that occur in Parkinson’s disease (PD) and trying to understand how this leads to disease. I am investigating how these molecular alterations lead to and cause the progression of the disease with the hope that this will allow us to develop a much better understanding of Parkinson’s.
My work uses genetic models of PD and I am particularly interested in how mutations in Glucocerebrosidase (GBA) and LRRK2 lead to PD.
I studied Biomedical Sciences at Cardiff University graduating in 2009 and going on to complete my PhD in 2013 at the same university. My PhD also concentrated on the mechanisms of Parkinson’s disease with particular interest in a loss of function role for alpha-synuclein.
Recommendations for measuring whisker movements and locomotion in mice with sensory, motor and cognitive deficits.
Simanaviciute U. et al, (2020), J Neurosci Methods, 331
Astrocytic striatal GABA transporter activity governs dopamine release and shows maladaptive downregulation in early parkinsonism
Roberts BM. et al, (2019)
An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.
Connor-Robson N. et al, (2019), Neurobiol Dis, 127, 512 - 526
RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes.
Booth HDE. et al, (2019), Neurobiol Dis, 129, 56 - 66
LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function.
Wallings R. et al, (2019), Hum Mol Genet